Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: protease-activated monoclonal antibodies - Bristol-Myers Squibb/CytomX Therapeutics

Next Previous
Drug Profile

Research programme: protease-activated monoclonal antibodies - Bristol-Myers Squibb/CytomX Therapeutics

Alternative Names: CTX-023; CTX-033; CTX-1003; CX 188; CX 2005; EGFR Probody Drug Conjugate; J43 antibody; PD-1 probody therapeutic - CytomX Therapeutics; Probodies; Probody™ cancer therapeutics - Bristol-Myers Squibb

Latest Information Update: 14 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CytomX Therapeutics
  • Developer Bristol-Myers Squibb; CytomX Therapeutics
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Epidermal growth factor receptor antagonists; Immunomodulators; Notch signalling pathway inhibitors; Programmed cell death 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Autoimmune disorders
  • Discontinued Inflammation

Most Recent Events

  • 11 Mar 2024 Preclinical development is still ongoing in Cancer in USA
  • 28 Dec 2023 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 05 May 2021 CytomX Therapeutics withdraws the phase I PROCLAIM-CX-188 trial in Solid tumours in USA, prior to enrolment (NCT03706274)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top